Phosphanilic acid is an organic compound with the formula H2NC6H4PO3H2. It is a white solid that is soluble in water and ethanol. Phosphanilic acid is synthesized by the reaction of aniline with phosphoric acid. Phosphanilic acid is used as an intermediate in the synthesis of other organic compounds. It is also used as a dye and a pharmaceutical agent. Phosphanilic acid has been investigated for its potential to inhibit the growth of certain types of cancer cells. It is also being studied for its potential to treat other conditions, such as diabetes and Alzheimer's disease. Phosphanilic acid is studied because it has shown promise in preclinical studies and has a unique chemical structure that could be exploited for therapeutic purposes.'
phosphanilic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 53590 |
| SCHEMBL ID | 232482 |
| MeSH ID | M0044075 |
| Synonym |
|---|
| nsc-55744 |
| nsc55744 |
| nsc 55744 |
| einecs 226-260-7 |
| phosphonic acid, (4-aminophenyl)- |
| p-phosphonoaniline |
| ai3-22255 |
| phosphanilic acid |
| brn 0388231 |
| nsc 417 |
| phosphonic acid, (p-aminophenyl)- |
| 4-phosphonoaniline |
| (4-aminophenyl)phosphonic acid |
| 5337-17-7 |
| (p-aminophenyl)phosphonic acid |
| nsc417 |
| nsc-417 |
| AKOS006283065 |
| 4-aminobenzenephosphonic acid |
| 5wcv1bq6m2 , |
| unii-5wcv1bq6m2 |
| 4-aminophenylphosphonic acid |
| SCHEMBL232482 |
| p-aminophenylphosphonic acid |
| OAOBMEMWHJWPNA-UHFFFAOYSA-N |
| DTXSID20201532 |
| c6h8no3p |
| AS-60231 |
| (4-amino-phenyl)-phosphonic acid |
| Q48937962 |
| mfcd00010580 |
| phosphonic acid, p-(4-aminophenyl)- |
| D88549 |
| CS-0453341 |
| (4-aminophenyl)phosphonicacid |
| EN300-183027 |
Phosphanilic acid is an antibacterial agent with a mode of action and antibacterial spectrum similar to those of sulfamethoxazole. It has potent antipseudomonal activity.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Phosphanilic acid is an antibacterial agent with a mode of action and antibacterial spectrum similar to those of sulfamethoxazole, with the exception that it has potent antipseudomonal activity. " | ( Bioavailability and metabolism of potassium phosphanilate in laboratory animals and humans. Hottendorf, GH; Lee, FH; Smyth, RD; Van Harken, DR; Vasiljev, M, 1980) | 1.7 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "We explored the antibacterial activity of phosphanilic acid (P), an analog of sulfanilic acid, alone and in combination with trimethoprim (T; TP, 1:5) with sulfamethoxazole (S) and co-trimoxazole, the combination of this sulfonamide with trimethoprim (TS, 1:5) as the reference." | ( Antibacterial activity of phosphanilic acid, alone and in combination with trimethoprim. Buck, RE; Chisholm, DR; Leitner, F; Misiek, M; Price, KE; Pursiano, TA; Tsai, YH, 1985) | 0.83 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " P was well absorbed parenterally but not orally in mice." | ( Antibacterial activity of phosphanilic acid, alone and in combination with trimethoprim. Buck, RE; Chisholm, DR; Leitner, F; Misiek, M; Price, KE; Pursiano, TA; Tsai, YH, 1985) | 0.57 |
| " Bioavailability studies in rats (50, 300, and 600 mg/kg, oral and subcutaneous), dogs (50, 150, and 450 mg/kg, oral and intravenous infusion), and humans (400 and 800 mg, oral) showed that the extent of oral absorption of potassium phosphanilate was low." | ( Bioavailability and metabolism of potassium phosphanilate in laboratory animals and humans. Hottendorf, GH; Lee, FH; Smyth, RD; Van Harken, DR; Vasiljev, M, 1980) | 0.26 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||